$1.19
-0.04 (-3.25%)
Open$1.22
Previous Close$1.23
Day High$1.22
Day Low$1.18
52W High$3.08
52W Low$1.08
Volume—
Avg Volume1.19M
Market Cap71.92M
P/E Ratio9.74
EPS$0.04
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,533.6% upside
Current
$1.19
$1.19
Target
$31.34
$31.34
$21.51
$31.34 avg
$48.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 64.59M | 59.98M | 30.93M |
| Net Income | 8.29M | 6.93M | -5,880,957 |
| Profit Margin | 12.8% | 12.2% | -19.0% |
| EBITDA | 6.10M | 5.38M | -8,827,347 |
| Free Cash Flow | — | — | -6,633,459 |
| Rev Growth | +7.7% | +7.7% | +18.4% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |